Cystadenocarcinoma, Serous
-
Subject Areas on Research
- A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
- ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
- An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
- An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
- Analgesic medication use and risk of epithelial ovarian cancer in African American women.
- Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
- Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
- Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
- BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
- BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
- Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions.
- CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
- Common variants at 19p13 are associated with susceptibility to ovarian cancer.
- Common variation in Nemo-like kinase is associated with risk of ovarian cancer.
- Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
- Differential expression of immune related genes in high-grade ovarian serous carcinoma.
- Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
- Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
- Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia.
- Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.
- GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
- Gene expression patterns that characterize advanced stage serous ovarian cancers.
- Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
- Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.
- Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
- Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
- Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.
- High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
- High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
- Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma.
- Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
- Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
- Increased levels of laminin in ascitic fluid of patients with ovarian cancer.
- Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
- Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types.
- Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
- Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
- Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.
- Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.
- Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
- Outcomes in surgical stage I uterine papillary serous carcinoma.
- Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.
- Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
- Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
- Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
- Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
- Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
- Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma.
- Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
- Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
- Prognostic gene expression signature for high-grade serous ovarian cancer.
- Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
- Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.
- Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
- Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
- Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
- Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
- Risk factors for ovarian cancers with and without microsatellite instability.
- Risk factors for ovarian cancers with and without microsatellite instability.
- Role of Increased n-acetylaspartate Levels in Cancer.
- STAT1 drives tumor progression in serous papillary endometrial cancer.
- Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
- Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma.
- Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
- Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
- Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
- The role of optimal debulking in advanced stage serous carcinoma of the uterus.
- p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
- Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute